Skip to main content

Month: June 2024

Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions

GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024. Details for the oral presentations are as follows:Session Title: Leveling Up Incretin-Based Therapy in Type 2 DiabetesSession Date/Time: Saturday, June 22, 2024, 4:30 PM – 6:00 PMPresentation Title: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory LipidsPresenter: John J. Suschak, Ph.D., Senior Director, Translational Science, AltimmunePresentation Date/Time: Saturday, June...

Continue reading

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) — Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate) for oral suspension. OLPRUVA® is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Visit OLPRUVA-Prescribing-Information.pdf (olpruva.com) to view the full Prescribing Information, including Important Safety Information. UCDs are rare genetic disorders that impair the body’s ability to remove excess...

Continue reading

Clubhouse Media Group, Inc. Announces Model and Comedian, Maya Spielman, Joins HoneyDrip.com

LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) — Clubhouse Media Group, Inc. (OTC: CMGR) (“Clubhouse Media Group”), a social media firm, today announced that Playboy model and comedian, Maya Spielman, has joined HoneyDrip.com. Spielman has performed stand up comedy in numerous venues, including Flappers Comedy Club and The Comedy Chateau. She has a large following, boasting 215k+ followers on Instagram alone. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a focus on the empowerment of creators. The site allows creators to connect and engage with fans and monetize exclusive content.“The HoneyDrip platform has attracted a vast array of professional creators,” said Alexandra Bolanos, Manager at HoneyDrip.com. “Our team works 24/7 and ensures that fans have access to the most exclusive and high...

Continue reading

BlueRush Announces Proposed Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, June 18, 2024 (GLOBE NEWSWIRE) — BlueRush Inc. (“BlueRush” or the “Company”) ‎‎‎(TSXV:BTV; ‎OTCQB:BTVRF), ‎a personalized video Software as a Service (“SaaS”) company, announced today a proposed non-brokered private placement financing pursuant to which BlueRush proposes to raise gross proceeds of up to $1,020,000 through the issuance of up to 68 units (a “Unit” or “Units”) of the ‎Company at $15,000 per Unit (the “Offering”). Each Unit shall consist of (i) 500,000 common shares of the ‎Company (the “Common Shares”) at a deemed price of $0.02 per Common Share, (ii) 500,000 transferable common share purchase warrants, with each warrant ‎‎entitling the holder thereof to acquire one additional Common Share ‎at a price of $0.05...

Continue reading

Abaxx Announces Investor Call

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, indirect majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, announces that it will be hosting an Investor Update call and presentation on Wednesday, July 3rd at 10:00 a.m. EST, with details outlined in this release. The purpose of the call is to provide investors with a corporate update following the projected late-June first trades on the Abaxx Commodity Futures Exchange and Clearinghouse. The Company will hold the investor presentation via Zoom Meetings on Wednesday, July 3rd...

Continue reading

Mesa Air Group Reports Second Quarter Fiscal 2024 Results

PHOENIX, June 18, 2024 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) today reported second quarter fiscal 2024 financial and operating results. Second Quarter Fiscal 2024 Update:Total operating revenues of $131.6 million Pre-tax income of $11.7 million, net income of $11.7 million or $0.28 per diluted share Adjusted net income1 of $6.3 million2 or $0.15 per diluted share Adjusted EBITDAR1 of $28.2 million Flew 99.85% controllable completion factorAdditional Updates:Closed on additional five engines associated with RASPRO finance lease since June 2024 announcement Renegotiated operating lease on two CRJ aircraft into a fully amortized buyout lease, reducing payments by $9.5 million over life of lease“Our second quarter results have begun to demonstrate an improvement in our business and...

Continue reading

Ashland achieves certification by Fair Wage Network

WILMINGTON, Del., June 18, 2024 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE:ASH) has strengthened its performance  towards environmental, social and governance (ESG) practices and a more just and equitable society through  a relationship with the Fair Wage Network (FWN) to understand living wages for the company’s 3,800 global employees. Following a rigorous and thorough process where compensation data for all employees was reviewed on an anonymous basis and steps were taken to remediate any pay gaps, Ashland achieved certification as a Global Living Wage Employer. Distinct from an audit approach, Fair Wage is an economically rigorous standard and methodology designed to assess, develop and optimize wage policies. Fair Wage encompasses sustainability dimensions like Living Wage and Equal Salary but is more comprehensive and systematically...

Continue reading

DAVIDsTEA Reports Financial Results for First Quarter of Fiscal 2024

Sales of $13.4 million Net loss of $2.6 million Adjusted EBITDA1 of negative $0.8 million Launches cold brew ready-to-drink sparkling iced tea collectionMONTREAL, June 18, 2024 (GLOBE NEWSWIRE) — DAVIDsTEA Inc. (TSX-Venture: DTEA) (“DAVIDsTEA” or the “Company”), a leading tea merchant in North America, announced today its first quarter results for the period ended May 4, 2024. “Despite tough economic conditions reducing overall demand, we are committed to turning our business around,” said Sarah Segal, Chief Executive Officer and Chief Brand Officer, DAVIDsTEA. “Brick-and-mortar sales grew by mid-single digits for the second consecutive quarter in Q1. Our specialty teas and brand equity resonate strongly with consumers, who want a sensory experience—smelling and sampling our teas—before buying. Therefore, we are focused on in-store...

Continue reading

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET. The R&D Day will feature presentations and a roundtable discussion from key opinion leader (KOL) guest speakers Carl D. Regillo, M.D., FACS, Professor of Ophthalmology at Thomas Jefferson University, Chief of Retina Service at Wills Eye Hospital, Founder of Wills Eye Clinical Retina Research Unit in Philadelphia, and Partner at Mid Atlantic Retina and Yasha S. Modi, M.D., Associate Professor of Vitreoretinal Surgery, Retinal Disease and Uveitis at New York University...

Continue reading

Standard Uranium Confirms Uranium Mineralization in Multiple Drill Holes at Atlantic Project; Provides Analytical Highlights from Winter Drill Program

VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) — Standard Uranium Ltd. (“Standard Uranium” or the “Company”) (TSX-V: STND) (OTCQB: STTDF) (Frankfurt: FWB:9SU) is pleased to announce a summary of analytical results from the inaugural winter 2024 drill program at its 3,061-hectare Atlantic Project (“Atlantic” or “the Project”) highlighting uranium mineralization in multiple drill holes. Atlantic is situated in the prolific eastern Athabasca Basin, northern Saskatchewan (Figure 1). The Project is currently under option (the “Option”) to ATCO Mining Inc. (the “Optionee”) an arms-length company listed on the Canadian Securities Exchange (CSE: ATCM). Pursuant to the Option, the Optionee can earn a 75% interest in Atlantic over three years. The Optionee-funded winter 2024 drill program contributes to satisfying the first...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.